| Drug Name |
Nefazodone hydrochloride |
| Drug ID |
BADD_D01547 |
| Description |
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or even death, with the incidence of severe liver damage was shown to be approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. |
| Indications and Usage |
For the treatment of depression. |
| Marketing Status |
approved; withdrawn |
| ATC Code |
N06AX06 |
| DrugBank ID |
DB01149
|
| KEGG ID |
D00819
|
| MeSH ID |
C051752
|
| PubChem ID |
54911
|
| TTD Drug ID |
D0X7DE
|
| NDC Product Code |
0093-1025; 0093-1026; 63629-7046; 63415-0015; 0093-1024; 0093-7113; 0093-7178 |
| UNII |
27X63J94GR
|
| Synonyms |
nefazodone | Serzone | Dutonin | Nefadar | nefazodone hydrochloride | Lin-Nefazodone | Menfazona | Rulivan | Apo-Nefazodone |
